Serotonin-specific reuptake inhibitors (SSRIs) are used to treat depressive disorders, which affect ∼10% of the population. Improving treatment requires a better understanding of the molecular pathways affected by these agents in different brain-cell populations. Addressing this issue has been difficult owing to the interconnectivity and complexity of brain-cell populations. Schmidt and colleagues overcame this challenge by using a transgenic mouse model involving a bacTRAP translational profiling approach to investigate the role of the p11 protein in responses to SSRIs. p11 is known to maintain serotonin receptors at the cell surface and to mediate antidepressant responses; some studies indicate that its expression is decreased in the brains of those with depression. The researchers tracked cells that were actively translating p11 protein and characterised their response to SSRIs. On treating mice with an SSRI, p11 expression was upregulated in a specific subset of cells in the frontal cortex, the layer 5 corticostriatal projection neurons, and resulted in induced expression of Htr4, encoding a serotonin receptor. Genetic ablation of p11 in this cell type prevented the upregulation of Htr4 and reduced the efficacy of SSRI treatment in mice. These data identify the cell type that is important in mediating the response to SSRIs, and provide unique mechanistic insight that might help to refine therapeutics for depression.
Antidepressant responses: key cell type identified
Antidepressant responses: key cell type identified. Dis Model Mech 1 July 2012; 5 (4): 415. doi:
Download citation file:
Advertisement
Cited by
DMM Journal Meeting 2024: Pre-clinical Modelling of Human Genetic Disease and Therapy

Register your interest for our 2024 Journal Meeting. Rapid advances in gene editing and genetic technologies have revolutionised our ability to model human genetic disease and provided new hope for gene therapies. At this Meeting, we will present the very latest advances in modelling human genetic disease. Find more information here.
A new call for papers is underway

Showcase your latest research in our upcoming special issue Translating Multiscale Research in Rare Disease, coordinated by DMM Editors Monica Justice, Karen Liu and Monkol Lek, and Guest Editor Kate Rauen. The deadline for submitting articles to the special issue is Monday 6 November 2023.
Moving towards heart success – Disease Models & Mechanisms Special Issue

DMM's most recent special issue compiles articles that aim to move heart failure to heart success by fundamentally addressing the roots of failure to identify curative strategies.
Adult zebrafish as advanced models of human disease

Editor-in-Chief Liz Patton and Editorial Board member Rich White discuss the unique advantages of adult zebrafish for studying human disease biology. Read the Open Access Editorial here.
The Forest of Biologists

The Forest of Biologists is a biodiversity initiative created by The Company of Biologists, with support from the Woodland Trust. For every Research and Review article published in Disease Models & Mechanisms a native tree is planted in a UK forest. In addition to this we are protecting and restoring ancient woodland and are dedicating these trees to our peer reviewers. Visit our virtual forest to learn more.
Other journals from
The Company of Biologists